Cargando…

Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study

Objective: To compare ertapenem therapy with piperacillin–tazobactam therapy for the management of acute pelvic infections. Methods: In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/po...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Subir, Higareda, Iliana, Angel-Muller, Edith, Ismail, Mahmoud, Hague, Caren, Adeyi, Ben, Woods, Gail L., Teppler, Hedy
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852268/
https://www.ncbi.nlm.nih.gov/pubmed/12839630
http://dx.doi.org/10.1155/S1064744903000048
_version_ 1782133021076357120
author Roy, Subir
Higareda, Iliana
Angel-Muller, Edith
Ismail, Mahmoud
Hague, Caren
Adeyi, Ben
Woods, Gail L.
Teppler, Hedy
author_facet Roy, Subir
Higareda, Iliana
Angel-Muller, Edith
Ismail, Mahmoud
Hague, Caren
Adeyi, Ben
Woods, Gail L.
Teppler, Hedy
author_sort Roy, Subir
collection PubMed
description Objective: To compare ertapenem therapy with piperacillin–tazobactam therapy for the management of acute pelvic infections. Methods: In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then randomized to ertapenem, 1 g once a day, or piperacillin–tazobactam, 3.375 g every 6 hours, both administered intravenously. Results: In total, 163 patients in the ertapenem group and 153 patients in the piperacillin–tazobactam group were clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common single pathogen was Escherichia coli . At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection. The frequency and severity of drug-related adverse events were generally similar in both groups. Conclusions: In this study, ertapenem was as effective as piperacillin–tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin–tazobactam.
format Text
id pubmed-1852268
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-18522682007-04-16 Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study Roy, Subir Higareda, Iliana Angel-Muller, Edith Ismail, Mahmoud Hague, Caren Adeyi, Ben Woods, Gail L. Teppler, Hedy Infect Dis Obstet Gynecol Research Article Objective: To compare ertapenem therapy with piperacillin–tazobactam therapy for the management of acute pelvic infections. Methods: In a multicenter, double-blind study, 412 women with acute pelvic infection were assigned to one of two strata, namely obstetric/postpartum infection or gynecologic/postoperative infection, and were then randomized to ertapenem, 1 g once a day, or piperacillin–tazobactam, 3.375 g every 6 hours, both administered intravenously. Results: In total, 163 patients in the ertapenem group and 153 patients in the piperacillin–tazobactam group were clinically evaluable. The median duration of therapy was 4.0 days in both treatment groups. The most common single pathogen was Escherichia coli . At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection. The frequency and severity of drug-related adverse events were generally similar in both groups. Conclusions: In this study, ertapenem was as effective as piperacillin–tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin–tazobactam. Hindawi Publishing Corporation 2003 /pmc/articles/PMC1852268/ /pubmed/12839630 http://dx.doi.org/10.1155/S1064744903000048 Text en Copyright © 2003 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Roy, Subir
Higareda, Iliana
Angel-Muller, Edith
Ismail, Mahmoud
Hague, Caren
Adeyi, Ben
Woods, Gail L.
Teppler, Hedy
Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study
title Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study
title_full Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study
title_fullStr Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study
title_full_unstemmed Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study
title_short Ertapenem Once a Day Versus Piperacillin–Tazobactam Every 6 Hours for Treatment of Acute Pelvic Infections: A Prospective, Multicenter, Randomized, Double-Blind Study
title_sort ertapenem once a day versus piperacillin–tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852268/
https://www.ncbi.nlm.nih.gov/pubmed/12839630
http://dx.doi.org/10.1155/S1064744903000048
work_keys_str_mv AT roysubir ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy
AT higaredailiana ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy
AT angelmulleredith ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy
AT ismailmahmoud ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy
AT haguecaren ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy
AT adeyiben ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy
AT woodsgaill ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy
AT tepplerhedy ertapenemonceadayversuspiperacillintazobactamevery6hoursfortreatmentofacutepelvicinfectionsaprospectivemulticenterrandomizeddoubleblindstudy